Key result
Platelet-activating factor induced a dose-dependent decrease in coronary flow and ventricular function in isolated guinea pig hearts, impairing diastolic function more than systolic function.
Why the study?
Does Platelet-activating factor impair myocardial contraction and relaxation in isolated guinea pig hearts?
Does Platelet-activating factor impair myocardial contraction and relaxation in isolated guinea pig hearts?
Platelet-activating factor exerts direct cardiodepressive effects, impairing ventricular diastolic function more than systolic function, which can be abolished by a PAF antagonist.
Does not alter clinical practice; leaves open PAF's role in human myocardial dysfunction.
Platelet-activating factor (PAF) is an important mediator of cardiovascular shock owing to immunologic reactions, including anaphylaxis and endotoxaemia. Previous studies have shown that PAF is a potent cardio-depressive agent causing a marked coronary constriction and a sustained impairment of myocardial contractility. In this study, we attempted to characterize further the prolonged PAF effects on coronary circulation and myocardial contractile force in isolated guinea pig hearts perfused at constant pressure (60 cm H2O) or constant flow which was adjusted to a level of 100% above basal flow. In addition, the PAF-induced changes of ventricular systolic and diastolic function were distinguished. In the hearts perfused at constant pressure, PAF induced a dose-dependent (0.57, 5.7, and 57 pmol/min) decrease of coronary flow rates, left ventricular pressure (LVP), LV contraction (peak positive dP/dt) and LV relaxation (peak negative dP/dt). The decrement of peak negative dP/dt was more pronounced than that of peak positive dP/dt. Maintenance of coronary flow rates only attenuated, but did not suppress, the PAF-induced ventricular malfunction, and it improved ventricular relaxation less than it did ventricular contraction. Pretreatment with the PAF antagonist WEB 2086 (19.7 nmol/min) almost completely abolished the effects of the highest PAF dose on coronary circulation and ventricular contractile parameters. We conclude that the cardiodepressive effects of PAF are due to coronary constriction and direct contractile events. Furthermore, PAF impairs ventricular diastolic function more than ventricular systolic function.
No takes yet. Share an insight, caveat, or question.
Felix et al. (1990) studied Cardiovascular shock / myocardial contractility. Platelet-activating factor (PAF) vs. Baseline / WEB 2086 pretreatment was evaluated on Coronary flow rates, left ventricular pressure, LV contraction, and LV relaxation. Platelet-activating factor induced a dose-dependent decrease in coronary flow and ventricular function in isolated guinea pig hearts, impairing diastolic function more than systolic function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: